Ferroptosis immunotherapy is promising for treating triple-negative breast cancer, but hindered by limited iron levels in tumor cells and a lack of specific immune responses. Here, the authors report a biohybrid system that enhances iron level by activating endogenous iron ions and replenishing exogenous iron ions and targets ferritin for synergistic ferroptosis immunotherapy.
- Shupei Sheng
- Yan Zhang
- Feng Lv
